title: Inhibitory effect of oversulfated fucoidan on invasion through reconstituted basement membrane by murine Lewis lung carcinoma.
abstract: We investigated the effects of native, oversulfated, and desulfated fucoidans and heparin on the invasion of 3 LL cells through Matrigel. Of the four polysaccharides tested, oversulfated fucoidan was the most potent inhibitor of tumor cell invasion and inhibited most potently and specifically the tumor cell adhesion to laminin. Sodium dodecyl sulfate-polyacrylamide gel electrophoretic analysis of the binding of elastase-cleaved laminin to fucoidan- and heparin-Sepharoses showed that both polysaccharides bound to the 62 and 56 kDa fragments. Pretreatment of 3LL cells with native or oversulfated fucoidan reduced their adhesive potency to laminin. The two fucoidans inhibited further the laminin binding of 3 LL cells which had been pretreated with a laminin-based pentapeptide, YIGSR. These results suggest that fucoidan specifically binds to not only the heparin binding domain(s) of laminin but also site(s) other than the cell surface laminin receptor. 3 LL cells secreted a 50 kDa form of urokinase-type plasminogen activator (u-PA). The extracellular level of u-PA activity was increased 1.7 times by addition of laminin but not type IV collagen. Oversulfated fucoidan most potently reduced the increased u-PA levels. Therefore, the reduction in in vitro invasiveness of 3 LL cells in response to either fucoidan or its oversulfated derivative may result from an inhibition of physical interaction between the tumor cells and the Matrigel (laminin), followed by a suppression of the laminin-induced increase in extracellular u-PA.
authors: Department of Biochemistry, Faculty of Pharmaceutical Sciences, Fukuoka University.
authors: S
authors: S
authors: Soeda
authors: S
authors: S
authors: Ishida
authors: H
authors: H
authors: Shimeno
authors: A
authors: A
authors: Nagamatsu
mesh_terms: D016475:3T3 Cells; D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001485:Basement Membrane / Q000473:pathology; D018827:Carcinoma, Lewis Lung / Q000473:pathology; D002448:Cell Adhesion / Q000187:drug effects; D006493:Heparin / Q000494:pharmacology; D007797:Laminin / Q000494:pharmacology; D051379:Mice; D009361:Neoplasm Invasiveness / Q000517:prevention & control*; D011134:Polysaccharides / Q000378:metabolism / Q000494:pharmacology*; D014568:Urokinase-Type Plasminogen Activator / Q000032:analysis
chemical_list: D000925:Anticoagulants; D000970:Antineoplastic Agents; D007797:Laminin; D011134:Polysaccharides; D006493:Heparin; C007789:fucoidan; D014568:Urokinase-Type Plasminogen Activator